Novavax (NVAX) Stock Forecast for 2023 – 2026. Sell or Buy?
Updated: December 2, 2023 (12:20)
Sector: HealthcareThe share price of Novavax, Inc. (NVAX) now
50/200 Day Moving Average: $6.7 / $7.58
This figure corresponds to the Average Price over the previous 50/200 days. For Novavax stocks, the 50-day moving average is the resistance level today.
For Novavax stocks, the 200-day moving average is the resistance level today.
Are you interested in Novavax, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Novavax stock price in 2023, 2024, 2025, 2026, 2027. How much will one Novavax share be worth in 2023 - 2027?
When should I take profit in Novavax stock? When should I record a loss on Novavax stock? What are analysts' forecasts for Novavax stock? What is the future of Novavax stock? We forecast Novavax stock performance using neural networks based on historical data on Novavax stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Novavax stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2023, 2024, 2025, 2026 and 2027) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Novavax shares. This happens once a day.
Historical and forecast chart of Novavax stock
The chart below shows the historical price of Novavax stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Novavax stock price can be found in the table below.
Long-term forecasts by years.
Novavex, Inc. Together with its subsidiary Novavax AB, a late-stage biotechnology company, it discovers, develops and commercializes vaccines to prevent serious infectious diseases. The company’s leading vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate, which is in stage III clinical trials to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in phase III clinical trials for the treatment of seasonal influenza in the elderly. Its leading adjuvant is Matrix-M, which is used to enable the vaccine to enhance the amplitude of the immune response and qualitatively change it, and to allow the immune system to attack microorganisms, and also to allow immunization with much smaller doses of antigen. The company is also developing the RSV F vaccine for the elderly (60 years and older), which is in phase II clinical trials, as well as for healthy children aged six months to five years, who are in phase I clinical trials. In addition, it is developing candidate nanoparticle vaccines for clinical trials against the Ebola virus, which is in clinical trials stage I; and a combined respiratory vaccine to protect against influenza and RSV. In addition, the company is developing a COVID-19 vaccine against the pneumonia-like coronavirus, which is in the preclinical stage. Novavex, Inc. the company was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Dec 04 | 5.74 | 5.45 | 6.09 | 11.85 |
| Dec 05 | 5.87 | 5.65 | 6.22 | 10.09 |
| Dec 06 | 5.86 | 5.74 | 6.21 | 8.27 |
| Dec 07 | 5.39 | 5.26 | 5.55 | 5.53 |
| Dec 08 | 5.26 | 4.91 | 5.45 | 10.99 |
| Dec 09 | 5.73 | 5.35 | 6.11 | 14.16 |
| Dec 10 | 5.60 | 5.38 | 5.83 | 8.44 |
| Dec 11 | 5.66 | 5.39 | 5.90 | 9.55 |
| Dec 12 | 5.22 | 4.90 | 5.39 | 9.98 |
| Dec 13 | 5.14 | 4.81 | 5.31 | 10.29 |
| Dec 14 | 4.89 | 4.68 | 5.00 | 6.76 |
| Dec 15 | 5.16 | 5.05 | 5.49 | 8.83 |
| Dec 16 | 5.26 | 5.04 | 5.59 | 10.79 |
| Dec 17 | 5.17 | 4.97 | 5.49 | 10.59 |
| Dec 18 | 5.18 | 5.01 | 5.44 | 8.57 |
| Dec 19 | 4.97 | 4.71 | 5.30 | 12.43 |
| Dec 20 | 5.37 | 5.03 | 5.56 | 10.47 |
| Dec 21 | 5.77 | 5.52 | 6.13 | 11.09 |
| Dec 22 | 6.02 | 5.68 | 6.23 | 9.64 |
| Dec 23 | 6.02 | 5.73 | 6.33 | 10.60 |
| Dec 24 | 6.21 | 5.90 | 6.52 | 10.52 |
| Dec 25 | 6.29 | 6.12 | 6.68 | 9.26 |
| Dec 26 | 6.29 | 6.05 | 6.59 | 8.89 |
| Dec 27 | 6.27 | 6.12 | 6.42 | 4.88 |
| Dec 28 | 6.01 | 5.70 | 6.31 | 10.83 |
| Dec 29 | 6.54 | 6.19 | 6.86 | 10.93 |
| Dec 30 | 6.61 | 6.29 | 6.81 | 8.22 |
| Dec 31 | 6.75 | 6.40 | 7.08 | 10.64 |
| Jan 01 | 6.35 | 6.07 | 6.73 | 10.84 |
| Jan 02 | 6.57 | 6.14 | 7.00 | 13.97 |
Novavax Daily Price Targets
Novavax Stock Forecast 12-04-2023.
Forecast target price for 12-04-2023: $5.74.
Positive dynamics for Novavax shares will prevail with possible volatility of 10.592%.
Pessimistic target level: 5.45
Optimistic target level: 6.09
Novavax Stock Forecast 12-05-2023.
Forecast target price for 12-05-2023: $5.87.
Positive dynamics for Novavax shares will prevail with possible volatility of 9.167%.
Pessimistic target level: 5.65
Optimistic target level: 6.22
Novavax Stock Forecast 12-06-2023.
Forecast target price for 12-06-2023: $5.86.
Negative dynamics for Novavax shares will prevail with possible volatility of 7.639%.
Pessimistic target level: 5.74
Optimistic target level: 6.21
Novavax Stock Forecast 12-07-2023.
Forecast target price for 12-07-2023: $5.39.
Negative dynamics for Novavax shares will prevail with possible volatility of 5.244%.
Pessimistic target level: 5.26
Optimistic target level: 5.55
Novavax Stock Forecast 12-08-2023.
Forecast target price for 12-08-2023: $5.26.
Negative dynamics for Novavax shares will prevail with possible volatility of 9.903%.
Pessimistic target level: 4.91
Optimistic target level: 5.45
Novavax Stock Forecast 12-09-2023.
Forecast target price for 12-09-2023: $5.73.
Positive dynamics for Novavax shares will prevail with possible volatility of 12.404%.
Pessimistic target level: 5.35
Optimistic target level: 6.11
NVAX (NVAX) Monthly Stock Prediction for 2023
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Dec. | 6.74 | 5.91 | 7.51 | 21.27 |
Novavax forecast for this year
Novavax Stock Prediction for Dec 2023
An uptrend is forecast for this month with an optimal target price of $6.74428. Pessimistic: $5.91. Optimistic: $7.51
Novavax (NVAX) Monthly Stock Prediction for 2024
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 6.70 | 5.36 | 7.17 | 25.26 |
| Mar | 5.78 | 4.95 | 6.25 | 20.81 |
| Mar | 5.87 | 5.09 | 7.08 | 28.09 |
| Apr | 4.46 | 3.92 | 5.31 | 26.17 |
| May | 3.96 | 3.59 | 4.56 | 21.13 |
| Jun | 4.01 | 3.49 | 4.62 | 24.46 |
| Jul | 4.02 | 3.24 | 4.64 | 30.18 |
| Aug | 3.88 | 3.30 | 4.47 | 26.28 |
| Sep | 3.47 | 2.89 | 4.13 | 30.03 |
| Oct | 3.10 | 2.91 | 3.83 | 24.01 |
| Nov | 2.58 | 2.41 | 2.92 | 17.49 |
| Dec | 3.12 | 2.70 | 3.86 | 30.24 |
Novavax (NVAX) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 3.43 | 2.83 | 4.01 | 29.46 |
| Mar | 3.46 | 2.97 | 3.89 | 23.71 |
| Mar | 3.58 | 3.05 | 4.05 | 24.65 |
| Apr | 3.37 | 2.79 | 3.78 | 26.18 |
| May | 3.87 | 3.08 | 4.43 | 30.42 |
| Jun | 3.95 | 3.04 | 4.24 | 28.26 |
| Jul | 3.18 | 2.77 | 3.62 | 23.46 |
| Aug | 2.93 | 2.49 | 3.41 | 26.85 |
| Sep | 2.99 | 2.56 | 3.43 | 25.37 |
| Oct | 2.24 | 1.98 | 2.39 | 16.89 |
| Nov | 2.56 | 2.36 | 3.15 | 25.10 |
| Dec | 2.52 | 2.08 | 2.83 | 26.52 |
Novavax (NVAX) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 2.46 | 2.16 | 3.03 | 28.76 |
| Mar | 2.27 | 1.95 | 2.79 | 30.05 |
| Mar | 1.77 | 1.60 | 2.07 | 22.60 |
| Apr | 1.52 | 1.27 | 1.65 | 22.97 |
| May | 1.16 | 0.94 | 1.38 | 32.30 |
| Jun | 1.07 | 0.92 | 1.14 | 19.14 |
| Jul | 1.02 | 0.86 | 1.09 | 21.61 |
| Aug | 1.05 | 0.93 | 1.24 | 25.55 |
| Sep | 0.94 | 0.72 | 1.11 | 35.25 |
| Oct | 0.89 | 0.79 | 1.00 | 20.78 |
| Nov | 0.78 | 0.68 | 0.95 | 28.37 |
| Dec | 0.85 | 0.69 | 0.97 | 28.66 |
Novavax (NVAX) Monthly Stock Prediction for 2027
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 0.79 | 0.74 | 0.98 | 24.92 |
| Mar | 0.81 | 0.64 | 0.98 | 34.62 |
| Mar | 0.57 | 0.50 | 0.66 | 24.39 |
| Apr | 0.54 | 0.50 | 0.64 | 22.82 |
| May | 0.52 | 0.43 | 0.56 | 22.99 |
| Jun | 0.54 | 0.42 | 0.60 | 30.51 |
| Jul | 0.60 | 0.47 | 0.69 | 32.61 |
| Aug | 0.54 | 0.47 | 0.62 | 24.39 |
| Sep | 0.66 | 0.52 | 0.74 | 29.39 |
| Oct | 0.86 | 0.70 | 1.02 | 31.21 |
| Nov | 0.92 | 0.72 | 1.12 | 35.51 |
| Dec | 0.98 | 0.77 | 1.17 | 34.39 |
Novavax information and performance
20 FIRSTFIELD ROAD, GAITHERSBURG, MD, US
Market capitalization of the Novavax, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of NVAX shares in the company outstanding by the market price of one share.
EBITDA of Novavax is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Novavax (NVAX) stock dividend
Novavax last paid dividends on 01/01/1970. The next scheduled payment will be on 05/10/2019. The amount of dividends is $0 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
